Boston Scientific Corporation $BSX Stock Position Boosted by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 10.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,207,330 shares of the medical equipment provider’s stock after buying an additional 311,634 shares during the period. Russell Investments Group Ltd. owned approximately 0.22% of Boston Scientific worth $140,024,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BSX. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific in the 1st quarter valued at $28,000. Cassaday & Co Wealth Management LLC bought a new position in Boston Scientific during the 1st quarter worth about $32,000. Measured Wealth Private Client Group LLC increased its holdings in Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 387 shares in the last quarter. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $25,000. Finally, Nvwm LLC lifted its holdings in shares of Boston Scientific by 526.2% in the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 542 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. BTIG Research reduced their price target on Boston Scientific from $56.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Citigroup cut their price objective on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, October 29th. Jefferies Financial Group cut shares of Boston Scientific from a “buy” rating to a “hold” rating and reduced their target price for the stock from $60.00 to $46.00 in a report on Wednesday, October 28th. Finally, Argus downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $61.43.

Get Our Latest Research Report on BSX

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $44.33 on Monday. The stock has a 50 day moving average of $44.00 and a 200-day moving average of $54.50. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $104.61. The company has a market capitalization of $64.25 billion, a P/E ratio of 18.78, a P/E/G ratio of 1.31 and a beta of 0.60. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business’s revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.